POTASSIUM CHLORIDE IN SODIUM CHLORIDE INJECTION USP SOLUTION

Țară: Canada

Limbă: engleză

Sursă: Health Canada

Cumpara asta acum

Ingredient activ:

SODIUM CHLORIDE; POTASSIUM CHLORIDE

Disponibil de la:

BAXTER CORPORATION

Codul ATC:

B05BB01

INN (nume internaţional):

ELECTROLYTES

Dozare:

450MG; 150MG

Forma farmaceutică:

SOLUTION

Compoziție:

SODIUM CHLORIDE 450MG; POTASSIUM CHLORIDE 150MG

Calea de administrare:

INTRAVENOUS

Unități în pachet:

1000ML

Tip de prescriptie medicala:

Ethical

Zonă Terapeutică:

REPLACEMENT PREPARATIONS

Rezumat produs:

Active ingredient group (AIG) number: 0213340004; AHFS:

Statutul autorizaţiei:

MARKETED

Data de autorizare:

2008-03-31

Caracteristicilor produsului

                                Potassium Chloride in 0.45% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 1 of 14_
PRESCRIBING INFORMATION
POTASSIUM CHLORIDE IN 0.45% SODIUM CHLORIDE INJECTION, USP
IN PLASTIC CONTAINER
VIAFLEX
Container
20 mmol/L Potassium Chloride in 0.45% Sodium Chloride Injection
SOLUTION FOR INFUSION
Solutions Affecting the Electrolyte Balance
BAXTER CORPORATION
Mississauga, ON L5N 0C2
Date of Revision:
December 10, 2018
Control No. 221539
Potassium Chloride in 0.45% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 2 of 14_
TABLE OF CONTENTS
SUMMARY PRODUCT INFORMATION
....................................................................................3
INDICATIONS AND CLINICAL USE
..........................................................................................3
CONTRAINDICATIONS
...............................................................................................................3
WARNINGS AND PRECAUTIONS
..............................................................................................3
SPECIAL POPULATIONS
.............................................................................................................7
ADVERSE REACTIONS
................................................................................................................8
DRUG INTERACTIONS
................................................................................................................8
DOSAGE AND ADMINISTRATION
............................................................................................9
INSTRUCTIONS FOR USE AND HANDLING AND DISPOSAL
............................................10
DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
..................................11
OVERDOSE
..................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
........................................................................13
STORAGE AND STABILITY
..................
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Caracteristicilor produsului Caracteristicilor produsului franceză 10-12-2018